C2i Genomics Partners with Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection

NEW YORK & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--C2i Genomics, a cancer intelligence company, and Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership to develop whole-genome cancer reference materials. This resource will provide...

Click to view original post